Clinical outcomes at month 12 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND)

AUTHORS

S. Schneider¹, M. Sension², A. Dretler³, S. Lalla-Reddy⁴, C. Schubert⁵, D. Merrill⁵, D. Richardson⁶, B. Sherif⁶, L. Zografos⁶, C. Garris⁵


INSTITUTIONS

¹Infectious Disease Specialists of Long Beach, Long Beach, United States, ²Community AIDS Network (CAN) Community Health, Sarasota, United States, ³Infectious Disease Specialists of Atlanta, Decatur, United States, ⁴Lalla-Reddy Medical Corporation, Fountain View, United States, ⁵ViiV Healthcare, Durham, United States, ⁶RTI Health Solutions, Research Triangle Park, United States